A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: CELGENE INTERNATIONAL II SARL
- Phase: III
- Execution start: 11/12/2020
- End of execution: 30/07/2024
- PI: FRANCISCA HERNANDEZ MOHEDO